Genentech
A Member of the Roche Group

IMPORTANT DRUG WARNING

February 2026

Subject: Risks with Use of ALECENSA® (alectinib): Severe Hypertriglyceridemia

Dear Health Care Provider:

The purpose of this letter is to inform you of important safety information for Alecensa (alectinib). Alecensa is indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test. Additionally, Alecensa is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test.

Serious Risks With Use of Alecensa

- Hypertriglyceridemia, including severe and life-threatening events, has been identified as a new Adverse Drug Reaction of Alecensa.
- Severe hypertriglyceridemia is considered a medical emergency, as it may lead to acute pancreatitis.
- Five severe to life-threatening medically confirmed hypertriglyceridemia cases were reported under Alecensa treatment in the post-marketing setting. Three of these cases resulted in the complication of life-threatening pancreatitis, all of which ultimately recovered upon treatment. One of these cases had a positive rechallenge of life-threatening hypertriglyceridemia upon Alecensa resumption. The onset of these serious cases ranged between 6 weeks and 1 year after the start of Alecensa treatment.

The Alecensa Prescribing Information will be updated to describe this adverse drug reaction.

Prescriber Action

- Counsel patients about the risks and benefits of Alecensa, including that Hypertriglyceridemia is a newly identified risk.
- Patients should have a baseline blood triglyceride measurement before starting Alecensa, as well as periodically while on treatment.
- Patients should be monitored for symptoms indicative of acute pancreatitis, particularly in patients at increased risk for pancreatitis.
- If severe (blood triglycerides >500 to 1000 mg/dL or >5.7 to 11.4 mmol/L) or life-threatening (blood triglycerides >1000 mg/dL or >11.4 mmol/L) elevations of blood triglycerides occur, Alecensa should be temporarily withheld until recovery to at least

moderate hypertriglyceridemia (i.e., until blood triglycerides are ≤500 mg/dL or ≤5.7 mmol/L). Risk factors for pancreatitis should be evaluated in such patients, and treatable risk factors should be addressed before resuming treatment with Alecensa. Alecensa may be resumed at the same dose, with triglyceride levels monitored regularly in such patients.

Background on the Safety Concern

- Cumulative data from clinical studies and postmarketing sources identified hypertriglyceridemia as a new risk for Alecensa, with hypertriglyceridemia adverse events of any grade severity reported for 4.3% of patients from pivotal clinical trials, and severe hypertriglyceridemia adverse events reported for 1.5% of patients from pivotal trials. Triglycerides were not consistently monitored in clinical trials. Laboratory data from 3 clinical trials in which triglycerides were measured showed an increase from baseline, and the majority of shifts from baseline were from normal to grade 1 (150mg/dL- 300mgdL; 1.71mmol/L-3.42mmol/L), however, events of grade ≥ 3 laboratory elevations were also reported in these clinical trials.
- Overall, the observed hypertriglyceridemia cases were mostly of mild and moderate severity.
- Please also refer to the information provided above in **Serious Risks with Use of Alecensa**.

The corresponding updates to the Prescribing Information will be forthcoming.

Reporting Adverse Events / Product Complaints and Company Contact

Health Care Providers should report any adverse events suspected to be associated with the use of Alecensa to Genentech at 1-888-835-2555. Alternatively, this information may be reported to FDA's MedWatch reporting system by phone (1-800-FDA-1088) or online (www.fda.gov/medwatch).

Please report any product complaint suspected to be associated with the use of Alecensa to Genentech at (800) 334-0290.

Should you have any questions about the information in this letter or the safe and effective use of Alecensa, please feel free to contact us at: Genentech Medical Information/Communications Department at (800) 821-8590.

This letter is not intended as a complete description of the benefits and risks related to the use of Alecensa. Please refer to the enclosed full prescribing information and patient information. The Alecensa prescribing information will be revised in consultation with the FDA and posted on gene.com and alecensa.com as soon as possible.

Sincerely,

Charlotte Owens

Charlotte Owens, M.D.
SVP, Head of U.S. Medical